IL270749A - A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure - Google Patents

A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure

Info

Publication number
IL270749A
IL270749A IL270749A IL27074919A IL270749A IL 270749 A IL270749 A IL 270749A IL 270749 A IL270749 A IL 270749A IL 27074919 A IL27074919 A IL 27074919A IL 270749 A IL270749 A IL 270749A
Authority
IL
Israel
Prior art keywords
receptor
fpr2
lipoxin
alx
agonist
Prior art date
Application number
IL270749A
Other languages
English (en)
Hebrew (he)
Inventor
Jacek Ostrowski
Ricardo Garcia
Nicholas R Wurtz
Nancy Leigh Carson
Original Assignee
Bristol Myers Squibb Co
Jacek Ostrowski
Ricardo Garcia
Nicholas R Wurtz
Nancy Leigh Carson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL270749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Jacek Ostrowski, Ricardo Garcia, Nicholas R Wurtz, Nancy Leigh Carson filed Critical Bristol Myers Squibb Co
Publication of IL270749A publication Critical patent/IL270749A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL270749A 2017-05-22 2019-11-18 A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure IL270749A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
IL270749A true IL270749A (en) 2020-01-30

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270749A IL270749A (en) 2017-05-22 2019-11-18 A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure

Country Status (15)

Country Link
US (1) US20200069644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020520948A (cg-RX-API-DMAC7.html)
KR (1) KR20200006595A (cg-RX-API-DMAC7.html)
CN (1) CN110662538A (cg-RX-API-DMAC7.html)
AU (1) AU2018273382A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024185A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003325A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992704A1 (cg-RX-API-DMAC7.html)
IL (1) IL270749A (cg-RX-API-DMAC7.html)
MX (1) MX2019013926A (cg-RX-API-DMAC7.html)
PE (1) PE20200402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018217684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022035923A1 (en) 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
WO2022076764A1 (en) * 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
EP3305763B1 (en) * 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
AU2018273382A1 (en) 2020-01-16
EP3630097A1 (en) 2020-04-08
CL2019003325A1 (es) 2020-04-17
CO2019013015A2 (es) 2020-01-17
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
WO2018217684A1 (en) 2018-11-29
CN110662538A (zh) 2020-01-07
KR20200006595A (ko) 2020-01-20
CA3064291A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
PE20200402A1 (es) 2020-02-26
JP2020520948A (ja) 2020-07-16
EA201992704A1 (ru) 2020-03-19

Similar Documents

Publication Publication Date Title
PL3989972T3 (pl) Agoniści receptora glukagonopodobnego peptydu 1
ZA202006115B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
IL267660A (en) Method for treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to gastric inhibitory peptide receptor antagonists
IL259468A (en) The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease
IL261846A (en) A method for cleaning glucagon-like peptide analogues
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
CA3263567A1 (en) Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
MX2019013926A (es) Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca.
IL290137A (en) Application of a polypeptide or derivative thereof
IL270199A (en) Peptides for the treatment of diabetes
ZA202006157B (en) Pharmaceutical composition of kor receptor agonist
HUE069752T2 (hu) Adaptív Compton kamera orvosi képalkotáshoz
HUE062092T2 (hu) Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló
EP3549948A4 (en) AGONISTIC PEPTIDE FOR ADIPONECTIN RECEPTOR
HK40022853A (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
IL284029B1 (en) Peptides for the treatment and prevention of diabetes and related disorders
HUE064558T2 (hu) Fájdalom kezelése 3-as szerotoninreceptor agonistájával
HK40023936A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
HK40002410A (en) Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
AU2016900635A0 (en) Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain